Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals

Cell Host and Microbe

Volumn 20, Issue 3, 2016, Pages 368-380

  Baxter, Amy E ^a,b   Niessl, Julia ^a,b   Fromentin, Rémi ^a   Richard, Jonathan ^a   Porichis, Filippos ^b,c   Charlebois, Roxanne ^a   Massanella, Marta ^a   Brassard, Nathalie ^a   Alsahafi, Nirmin ^a,f   Delgado, Gloria Gabrielle ^a   Routy, Jean Pierre ^d   Walker, Bruce D ^b,c,e   Finzi, Andrés ^a,f   Chomont, Nicolas ^a   Kaufmann, Daniel E ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN; GAG PROTEIN; INGENOL; IONOMYCIN; VIRAL PROTEIN; MESSENGER RNA; POL PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RNA HYBRIDIZATION; SINGLE CELL ANALYSIS; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; CELL CULTURE; FLUORESCENCE IN SITU HYBRIDIZATION; HIV INFECTIONS; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, MESSENGER; SINGLE-CELL ANALYSIS; SUSTAINED VIROLOGIC RESPONSE;

EID: 84995654922     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2016.07.015     Document Type: Article

References (37)

1. Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M., Parker, D.C., Anderson, E.M., Kearney, M.F., Strain, M.C., et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487 (2012), 482–485.
2. Argañaraz, E.R., Schindler, M., Kirchhoff, F., Cortes, M.J., Lama, J., Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication. J. Biol. Chem. 278 (2003), 33912–33919.
3. Bagnarelli, P., Valenza, A., Menzo, S., Sampaolesi, R., Varaldo, P.E., Butini, L., Montroni, M., Perno, C.F., Aquaro, S., Mathez, D., et al. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J. Virol. 70 (1996), 7603–7613.
4. Banga, R., Procopio, F.A., Noto, A., Pollakis, G., Cavassini, M., Ohmiti, K., Corpataux, J.M., de Leval, L., Pantaleo, G., Perreau, M., PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22 (2016), 754–761.
5. Brenchley, J.M., Hill, B.J., Ambrozak, D.R., Price, D.A., Guenaga, F.J., Casazza, J.P., Kuruppu, J., Yazdani, J., Migueles, S.A., Connors, M., et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J. Virol. 78 (2004), 1160–1168.
6. Bruner, K.M., Hosmane, N.N., Siliciano, R.F., Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 23 (2015), 192–203.
7. Burgess, A., Vigneron, S., Brioudes, E., Labbé, J.C., Lorca, T., Castro, A., Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc. Natl. Acad. Sci. USA 107 (2010), 12564–12569.
8. Burton, D.R., Ahmed, R., Barouch, D.H., Butera, S.T., Crotty, S., Godzik, A., Kaufmann, D.E., McElrath, M.J., Nussenzweig, M.C., Pulendran, B., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12 (2012), 396–407.
9. Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F.A., Yassine-Diab, B., Boucher, G., Boulassel, M.R., Ghattas, G., Brenchley, J.M., et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15 (2009), 893–900.
10. DeChristopher, B.A., Loy, B.A., Marsden, M.D., Schrier, A.J., Zack, J.A., Wender, P.A., Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat. Chem. 4 (2012), 705–710.
11. Deeks, S.G., HIV: Shock and kill. Nature 487 (2012), 439–440.
12. Deeks, S.G., Autran, B., Berkhout, B., Benkirane, M., Cairns, S., Chomont, N., Chun, T.W., Churchill, M., Di Mascio, M., Katlama, C., et al., International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12 (2012), 607–614.
13. DeMaster, L.K., Liu, X., VanBelzen, D.J., Trinité, B., Zheng, L., Agosto, L.M., Migueles, S.A., Connors, M., Sambucetti, L., Levy, D.N., et al. A subset of CD4/CD8 double-negative T cells expresses HIV proteins in patients on antiretroviral therapy. J. Virol. 90 (2016), 2165–2179.
14. Eriksson, S., Graf, E.H., Dahl, V., Strain, M.C., Yukl, S.A., Lysenko, E.S., Bosch, R.J., Lai, J., Chioma, S., Emad, F., et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog., 9, 2013, e1003174.
15. Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn, T.C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997), 1295–1300.
16. Graf, E.H., Pace, M.J., Peterson, B.A., Lynch, L.J., Chukwulebe, S.B., Mexas, A.M., Shaheen, F., Martin, J.N., Deeks, S.G., Connors, M., et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS ONE, 8, 2013, e71879.
17. Ho, Y.C., Shan, L., Hosmane, N.N., Wang, J., Laskey, S.B., Rosenbloom, D.I., Lai, J., Blankson, J.N., Siliciano, J.D., Siliciano, R.F., Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155 (2013), 540–551.
18. Hurst, J., Hoffmann, M., Pace, M., Williams, J.P., Thornhill, J., Hamlyn, E., Meyerowitz, J., Willberg, C., Koelsch, K.K., Robinson, N., et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat. Commun., 6, 2015, 8495.
19. Jiang, G., Mendes, E.A., Kaiser, P., Sankaran-Walters, S., Tang, Y., Weber, M.G., Melcher, G.P., Thompson, G.R. 3rd, Tanuri, A., Pianowski, L.F., et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS 28 (2014), 1555–1566.
20. Karn, J., Stoltzfus, C.M., Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb. Perspect. Med., 2, 2012, a006916.
21. Kaufmann, D.E., Kavanagh, D.G., Pereyra, F., Zaunders, J.J., Mackey, E.W., Miura, T., Palmer, S., Brockman, M., Rathod, A., Piechocka-Trocha, A., et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8 (2007), 1246–1254.
22. Kiselinova, M., De Spiegelaere, W., Buzon, M.J., Malatinkova, E., Lichterfeld, M., Vandekerckhove, L., Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathog., 12, 2016, e1005472.
23. Kulpa, D.A., Chomont, N., HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?. J. Virus Erad. 1 (2015), 59–66.
24. Lahm, H.W., Stein, S., Characterization of recombinant human interleukin-2 with micromethods. J. Chromatogr. A 326 (1985), 357–361.
25. Locci, M., Havenar-Daughton, C., Landais, E., Wu, J., Kroenke, M.A., Arlehamn, C.L., Su, L.F., Cubas, R., Davis, M.M., Sette, A., et al., International AIDS Vaccine Initiative Protocol C Principal Investigators. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39 (2013), 758–769.
26. Morita, R., Schmitt, N., Bentebibel, S.E., Ranganathan, R., Bourdery, L., Zurawski, G., Foucat, E., Dullaers, M., Oh, S., Sabzghabaei, N., et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34 (2011), 108–121.
27. Patterson, B.K., McCallister, S., Schutz, M., Siegel, J.N., Shults, K., Flener, Z., Landay, A., Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 15 (2001), 1635–1641.
28. Perreau, M., Savoye, A.L., De Crignis, E., Corpataux, J.M., Cubas, R., Haddad, E.K., De Leval, L., Graziosi, C., Pantaleo, G., Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210 (2013), 143–156.
29. Porichis, F., Hart, M.G., Griesbeck, M., Everett, H.L., Hassan, M., Baxter, A.E., Lindqvist, M., Miller, S.M., Soghoian, D.Z., Kavanagh, D.G., et al. High-throughput detection of miRNAs and gene-specific mRNA at the single-cell level by flow cytometry. Nat. Commun., 5, 2014, 5641.
30. Sallusto, F., Geginat, J., Lanzavecchia, A., Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22 (2004), 745–763.
31. Schwartz, O., Maréchal, V., Le Gall, S., Lemonnier, F., Heard, J.M., Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2 (1996), 338–342.
32. Siliciano, J.D., Siliciano, R.F., Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol. Biol. 304 (2005), 3–15.
33. Soriano-Sarabia, N., Bateson, R.E., Dahl, N.P., Crooks, A.M., Kuruc, J.D., Margolis, D.M., Archin, N.M., Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J. Virol. 88 (2014), 14070–14077.
34. Spina, C.A., Anderson, J., Archin, N.M., Bosque, A., Chan, J., Famiglietti, M., Greene, W.C., Kashuba, A., Lewin, S.R., Margolis, D.M., et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog., 9, 2013, e1003834.
35. Stevenson, M., Stanwick, T.L., Dempsey, M.P., Lamonica, C.A., HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9 (1990), 1551–1560.
36. Swanstrom, R., Coffin, J., HIV-1 pathogenesis: the virus. Cold Spring Harb. Perspect. Med., 2, 2012, a007443.
37. Vandergeeten, C., Fromentin, R., Merlini, E., Lawani, M.B., DaFonseca, S., Bakeman, W., McNulty, A., Ramgopal, M., Michael, N., Kim, J.H., et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J. Virol. 88 (2014), 12385–12396.